RoyMitchelFleischmannMD

PubMed

• Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE.
  Ricardo Blanco, Filip Van den Bosch, Louis Bessette, Yanna Song, Sara K Penn, Erin McDearmon-Blondell, Nasser Khan, Kelly Chan, Eduardo Mysler, Roy Fleischmann> ;Rheumatology and Therapy. 2024 Mar 18
• TYK2: an emerging therapeutic target in rheumatic disease.
  Eric Morand, Joseph F Merola, Yoshiya Tanaka, Dafna Gladman, Roy Fleischmann> ;Nature Reviews. Rheumatology. 2024 Apr 1
• Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician.
  Szekanecz, Z., Buch, M., Galloway, J., Kristensen, L., Hamar, A., Charles-Schoeman, C., Karpouzas, G., Ytterberg, S., Fleischmann, R.> ;Nature Reviews. Rheumatology. 2024 Mar 1
• 2 citations
  Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician.
  Zoltán Szekanecz, Maya H Buch, Christina Charles-Schoeman, James Galloway, George A Karpouzas, Lars Erik Kristensen, Steven R Ytterberg, Attila Hamar, Roy Fleischmann> ;Nature Reviews. Rheumatology. 2024 Feb 1
• 1 citations
  Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomis...
  Alvarez, D., Cox, D., Ianos, C., Zhang, W., Cronenberger, C., Wang, K., Fleischmann, R., Saikali, W., Lakhanpal, S.> ;The Lancet. Rheumatology. 2023 Sep 1
• 2 citations
  Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis.
  Paul Emery, Yoshiya Tanaka, Vivian P Bykerk, Thomas W J Huizinga, Gustavo Citera, Clifton O Bingham 3rd, Subhashis Banerjee, Benjamin P Soule, Marleen Nys, Sean E Conn...> ;Rheumatology and Therapy. 2023 Jun 1
• Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis.
  Gerd R Burmester, Vibeke Strand, Alan J Kivitz, Chih-Chi Hu, Sheldon Wang, Hubert van Hoogstraten, Gabriella L Klier, Roy Fleischmann> ;Rheumatology. 2023 Oct 3
• Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison.
  Thomas Huizinga, Ernest Choy, Amy Praestgaard, Hubert van Hoogstraten, Patrick R LaFontaine, Patricia Guyot, Daniel Aletaha, Ulf Müller-Ladner, Yoshiya Tanaka, Jeffrey...> ;Rheumatology and Therapy. 2023 Jun 1
• 1 citations
  Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate.
  Roy Fleischmann, Boulos Haraoui, Maya H Buch, David Gold, Gosford Sawyerr, Harry Shi, Annette Diehl, Kristen Lee> ;Rheumatology and Therapy. 2023 Apr 1
• 1 citations
  Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated pro...
  Chun Wu, Yanhua Hu, Peter Schafer, Sean E Connolly, Robert Wong, Signe Holm Nielsen, Anne-Christine Bay-Jensen, Paul Emery, Yoshiya Tanaka, Vivian P Bykerk, Clifton O ...> ;RMD Open. 2022 Dec 1
• Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis.
  Kurt de Vlam, Philip J Mease, Andrew G Bushmakin, Roy Fleischmann, Alexis Ogdie, Valderilio F Azevedo, John Woolcott, Joseph C Cappelleri, Lara Fallon, Peter C Taylor,...> ;Rheumatology and Therapy. 2022 Oct 1
• 2 citations
  Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-...
  Eduardo Mysler, Yoshiya Tanaka, Arthur Kavanaugh, Daniel Aletaha, Peter C Taylor, In-Ho Song, Tim Shaw, Yanna Song, Ryan DeMasi, Mira Ali, Roy Fleischmann> ;Rheumatology. 2023 May 2
• 1 citations
  Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to ...
  Roy Fleischmann, Alan Friedman, Edit Drescher, Atul Singhal, Gregorio Cortes-Maisonet, Thao Doan, Wenjing Lu, Zailong Wang, Ahmed Nader, William Housley, Stanley Cohen...> ;The Lancet. Rheumatology. 2022 Jun 1
• 4 citations
  Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis.
  Roy M Fleischmann, Amy E Bock, Wuyan Zhang, Charles M Godfrey, Ivana Vranic, Carol Cronenberger, Eva Dokoupilová> ;Rheumatology and Therapy. 2022 Jun 1
• 1 citations
  Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis.
  Roy Fleischmann, Kyle Hayes, Sung-Woo Ahn, George J Wan, Mary Panaccio, Daniel Karlsson, Daniel E Furst> ;Rheumatology and Therapy. 2022 Apr 1
• 4 citations
  Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis.
  Omar Jabado, Michael A Maldonado, Michael Schiff, Michael E Weinblatt, Roy Fleischmann, William H Robinson, Aiqing He, Vishal Patel, Alex Greenfield, Jasmine Saini, Da...> ;Rheumatology and Therapy. 2022 Apr 1
• 4 citations
  Post Hoc Analysis of the Correlation Between Patient-Reported Outcomes and Clinical Response to Repository Corticotropin Injection for Persistently Active Rheumatoid A...
  Roy Fleischmann, Kyle Hayes, Sung-Woo Ahn, George J Wan, Mary P Panaccio, Daniel Karlsson, Daniel E Furst> ;Rheumatology and Therapy. 2022 Apr 1
• 14 citations
  Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy.
  Peter C Taylor, Rieke Alten, Jose María Álvaro Gracia, Yuko Kaneko, Chad Walls, Amanda Quebe, Bochao Jia, Natalia Bello, Jorge Ross Terres, Roy Fleischmann> ;RMD Open. 2022 Mar 1
• 38 citations
  Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.
  Roy Fleischmann, Eduardo Mysler, Louis Bessette, Charles G Peterfy, Patrick Durez, Yoshiya Tanaka, Jerzy Swierkot, Nasser Khan, Xianwei Bu, Yihan Li, In-Ho Song> ;RMD Open. 2022 Feb 1
• 3 citations
  Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis.
  Philip G. Conaghan, Stanley Cohen, Gerd R Burmester, Eduardo Mysler, Peter Nash, Yoshiya Tanaka, William F. C. Rigby, Jayeshkumar Patel, T. Shaw, Keith A. Betts, Panka...> ;Rheumatology and Therapy. 2021 Nov 23
• 7 citations
  Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimum...
  Roy Fleischmann, Daniel F. Alvarez, Amy E. Bock, Carol Cronenberger, Ivana Vranic, Wuyan Zhang, Rieke Alten> ;Arthritis Research & Therapy. 2021 Sep 25
• Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis.
  Roy Fleischmann> ;Clinical Rheumatology. 2021 Sep 24
• 5 citations
  Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND.
  Désirée van der Heijde, Cynthia E. Kartman, Li Xie, Scott Beattie, Douglas E Schlichting, Daojun Mo, Patrick Durez, Yoshiya Tanaka, Roy Fleischmann> ;The Journal of Rheumatology. 2021 Sep 15
• 18 citations
  Filgotinib or Lanraplenib in Moderate to Severe Cutaneous Lupus Erythematosus: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study.
  Victoria P. Werth, Roy Fleischmann, Michael Robern, Zahi Touma, Iyabode Tiamiyu, Oksana Gurtovaya, Alena Pechonkina, Afsaneh Mozaffarian, Bryan R. Downie, Franziska Ma...> ;Rheumatology. 2021 Sep 8
• 2 citations
  Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus ...
  Tsutomu Takeuchi, Roy Fleischmann, Noriko Iikuni, Harry Shi, Koshika Soma, Jerome Paulissen, Tomohiro Hirose, Josef S Smolen> ;Arthritis Research & Therapy. 2021 Aug 24
• Join now to see all

Lectures

• A Comparative Clinical Study of PF-06410293, a Candidate Adalimumab Biosimilar, and Adalimumab Reference Product (Humira®) in the Treatment of Active Rheumatoid Arthritis 
  Rheumatology Winter Clinical Symposium, Maui, Hawaii - 2/6/2013